U.S. Effort To Close Patent Loophole Seen Affecting Indian Generics
This article was originally published in PharmAsia News
Indian generics makers are expected to be among the most-affected by a U.S. decision to plug loopholes that allow brand-generic patent deals. The deals often involve a brand-name drug maker and generics makers reaching agreements to settle patent disputes. Ranbaxy Laboratories and Dr. Reddy's Laboratories have been involved in several settlements with major pharmas, helping to spark the U.S. Federal Trade Commission concern about anti-competitive practices. The agency threatened action to prevent the primary effect of the deals, which the FTC says delays the availability of the cheaper generics on the U.S. market. The action could include legislation to amend current law that allows the deals. (Click here for more
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.